Inquired about the status of SAP alignment with the FDA, reasons for the August to September deadline shift, and the minimum efficacy package required for a BLA submission if the primary endpoint is not met.

Management stated substantive discussions with FDA on SAP are complete, incorporating feedback, and they await final comments before database lock. The delay to September was due to patient follow-up. They confirmed that clinically significant exploratory endpoints could support a BLA, given FDA's regulatory flexibility for rare diseases. “We have already substantive discussions with the FDA in alignment regarding the endpoint strategy, which include both NIH-defined and and we have incorporated all the agency feedback into our statistical plan, statistical approach.”

Asked about the remaining CMC (Chemistry, Manufacturing, and Controls) items needed for a BLA filing in 2027.

Management indicated excellent progress with CMC, actively working with a provider for manufacturing transfer. They foresee no blockers for BLA filing with a positive FDA signal, believing they are best suited to handle manufacturing. “We have made excellent progress with our CMC. a provider that we are working actively with to transfer the manufacturing. I think everything looks to be a go.”

Questioned how events-based data is being collected for the 12-month endpoint and if sufficient survival data would be available for a BLA filing in September.

Management explained they are collecting long-term patient outcome data, with some patients having up to five years of data, and plan a long-term extension trial up to age 10. They confirmed having sufficient data to demonstrate long-term outcomes for a BLA submission in September. “We are collecting right before the database each patient. Some of the patients initiated the trials five years ago, and we have five years data. We are collecting survival status, we are collecting transplant status, This is going to have for all patients with different duration, depending on when patient initiated the treatment.”

LGVN

Longeveron (LGVN) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 12, 2026

Source: earnings call transcript

Executive summary

Longeveron Q2 FY26 — HLHS Data Readout Expected Mid-September, XPRIZE Finalist

Longeveron is at a pivotal juncture, with the highly anticipated ELPAS-2 data readout for HLHS expected in mid-September, alongside significant external validation as an XPRIZE HealthSpan finalist for age-related frailty. The company is actively pursuing partnerships to leverage its stem cell therapy, laramester cell, across its four development programs, aiming for efficient commercialization. While advancing its pipeline, the company faces increased operating expenses and a limited cash runway, necessitating strategic financial management.

Highlights

HLHS ELPAS-2 Phase 2b data readout expected mid-September, a primary near-term catalyst.
Selected as a finalist for the XPRIZE HealthSpan competition, receiving a $1 million award for age-related frailty.
IND application for Pediatric Dilated Cardiomyopathy (PDCM) became effective in July 2025, allowing direct advancement into a single Phase 2 clinical trial.
Strong foundational science with 52 issued patents and 5 FDA expedited designations (RMAT, Fast-Track, Orphan Drug, Rare Pediatric Disease).

Concerns

Net loss increased by $1.1 million or 22% to $6.1 million for Q2 2026 compared to Q2 2025.
General and administrative expenses increased by $0.6 million or 23% to $3.2 million for Q2 2026.
Cash and cash equivalents of $10.1 million are anticipated to fund operations only into Q4 2026.

Guidance & targets

Category	Target	Timeline	Confidence
HLHS ELPAS-2 Phase 2b data readout	Mid-September high materiality	Q3 · FY26	High
Pediatric Dilated Cardiomyopathy (PDCM) Phase 2 clinical trial initiation	2027 medium materiality	FY27	High
Cash runway	Into the fourth quarter of 2026 high materiality	Q4 · FY26	Medium
XPRIZE HealthSpan clinical trials	Through 2029 medium materiality	FY29	High
XPRIZE HealthSpan grand prize award	Up to $81 million medium materiality	FY29	Medium

Deals & partnerships

Major potential partners Development and commercialization partnerships for laramester cell

Company is actively exploring partnerships, especially after anticipated positive HLHS data. They have already had conversations with major potential partners.

Risks & headwinds

Limited cash runway Near-term (into Q4 2026)

Cash and cash equivalents of $10.1 million are anticipated to fund operations into Q4 2026.

Mitigation:Seeking partnerships for capital resources.

Increased operating expenses Q2 FY26

General and administrative expenses increased by $0.6 million or 23% to $3.2 million; R&D expenses increased by $0.2 million or 7% to $3.2 million.

Mitigation:Not explicitly stated, but implies need for efficient capital management and partnerships.

Net loss increase Q2 FY26

Net loss increased by $1.1 million or 22% to $6.1 million.

Mitigation:Not explicitly stated, but linked to increased expenses and need for partnerships.

Regulatory uncertainty for BLA if primary endpoint is missed Post-September ELPAS-2 readout

If RVEF (former primary endpoint) is not met in ELPAS-2.

Mitigation:FDA has expressed regulatory flexibility for rare pediatric diseases; company will pursue BLA based on clinically significant exploratory endpoints (transplant-free survival, hospitalization).

What to watch in Q3 FY26

HLHS ELPAS-2 data readout

Mid-September

Current Data expected mid-September

Target Positive top-line results

Why it matters

This is the primary near-term catalyst and could redefine the company's trajectory and partnership opportunities.

We expect to report that data readout in mid-September.

Find out whether LGVN delivers this. Inve re-checks your case every morning.

Q&A highlights

Asked for details on the regulatory submission timeline post-ELPAS-2 data, commercial scale-up, potential pricing, and how winning the XPRIZE would affect the age-related frailty development plan.

Management expects to pursue a BLA with a priority review voucher if HLHS data is positive, anticipating partnership to determine commercial aspects and pricing. For age-related frailty, they will seek a partner prior to potentially winning the XPRIZE, highlighting their unique position as a public company in longevity research.

“We don't see any blockers if we get good HLHS data to going to a BLA. with, I would remind you, a priority review voucher, which just recently sold for $215 million.”

asked by Ram Salivaro · answered by Steven Willard

3 min read 8 chapters

Detailed narrative

HLHS Program and Upcoming Data Readout

Longeveron's primary focus is its Hypoplastic Left Heart Syndrome (HLHS) program, with top-line results from the ELPAS-2 Phase 2b clinical trial evaluating laramester cell anticipated in mid-September. The trial is assessing objective measures including all-cause mortality, cardiac transplant-free survival, and major adverse cardiac events, which the FDA considers informative for efficacy.

Management believes that if successful, these data could lead to BLA filing and potential approval, leveraging existing FDA flexibility for rare pediatric diseases.

XPRIZE HealthSpan Recognition for Age-Related Frailty

The company's laramester cell therapy was selected as a finalist for the XPRIZE HealthSpan competition, receiving a $1 million award. This recognition validates the therapy's potential to increase six-minute walk distance in patients with age-related frailty, with clinical trials expected to continue through 2029. Longeveron is the only public company among the finalists, highlighting its position in cutting-edge longevity research.

Pediatric Dilated Cardiomyopathy (PDCM) Program Advancement

Longeveron is planning for a potential initiation in 2027 of a Phase 2 clinical trial for pediatric dilated cardiomyopathy (PDCM), a rare and serious cardiovascular disease. The IND application for laramester cell in PDCM became effective in July 2025, allowing direct advancement into a single Phase 2 registration trial, reflecting the high unmet medical need and regulatory flexibility for this indication.

Strategic Focus on Partnerships

Management emphasized exploring potential development and commercialization partnerships for laramester cell across its programs. They believe leveraging established pharmaceutical partners' commercial infrastructure, capital resources, and global reach represents the most efficient pathway to unlock the full value of their assets, particularly following the anticipated positive HLHS data.

Financial Overview and Cash Runway

For Q2 2026, Longeveron reported revenues of $0.3 million, a 10% decrease year-over-year due to the absence of contract manufacturing revenue. General and administrative expenses increased by 23% to $3.2 million, driven by higher legal and personnel costs, while R&D expenses rose 7% to $3.2 million due to increased clinical trial activities.

The net loss for the quarter was $6.1 million, up 22% from the prior year. The company's cash and cash equivalents of $10.1 million are projected to fund operations into Q4 2026.

Foundational Science and Regulatory Designations

Laramester cell is supported by strong foundational science, including multiple potential mechanisms of action (anti-inflammatory, provascular, pro-regenerative effects) and a portfolio of 52 issued patents. The therapy has received five FDA expedited designations, including Regenerative Medicine Advanced Therapy (RMAT), Fast-Track, Orphan Drug, and Rare Pediatric Disease, underscoring its potential and the urgent need for new treatments in its target indications.

Regulatory Pathway and SAP Alignment

Longeveron has had substantive discussions with the FDA regarding its Statistical Analysis Plan (SAP) for the ELPAS-2 trial, incorporating agency feedback on endpoint strategy. While awaiting final FDA comments on the SAP, the company intends to proceed with database lock and analysis based on the finalized plan.

Management expressed confidence that even if the former primary endpoint (RVEF) is not met, improvements in clinically significant exploratory endpoints like transplant-free survival and hospitalization could support a BLA submission, given the unmet need and FDA's regulatory flexibility.

Long-Term Patient Follow-up and Survival Data

The company is collecting long-term patient outcome data for the HLHS trial, with some patients having up to five years of data. They are also planning a long-term extension trial to follow patients up to 10 years of age, which has been discussed with the FDA.

This comprehensive data collection aims to provide sufficient evidence for long-term survival and transplant-free survival, which are considered critical for regulatory approval, potentially supporting accelerated or traditional BLA pathways.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.